194 related articles for article (PubMed ID: 15257945)
1. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
Tefferi A; Lasho TL; Brockman SR; Elliott MA; Dispenzieri A; Pardanani A
Haematologica; 2004 Jul; 89(7):871-3. PubMed ID: 15257945
[TBL] [Abstract][Full Text] [Related]
2. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
[TBL] [Abstract][Full Text] [Related]
3. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
4. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
[TBL] [Abstract][Full Text] [Related]
5. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Tefferi A; Levine RL; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Finke CM; Mullally A; Li CY; Pardanani A; Gilliland DG
Leukemia; 2009 May; 23(5):900-4. PubMed ID: 19262599
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
[TBL] [Abstract][Full Text] [Related]
8. Transient macular erythema with eosinophilia in a patient carrying the FIP1L1-PDGFRA fusion gene.
Yahara H; Satoh T; Hashimoto T; Yokozeki H
Br J Dermatol; 2007 Dec; 157(6):1284-7. PubMed ID: 17916194
[No Abstract] [Full Text] [Related]
9. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
Sorour Y; Dalley CD; Snowden JA; Cross NC; Reilly JT
Br J Haematol; 2009 Jul; 146(2):225-7. PubMed ID: 19466970
[No Abstract] [Full Text] [Related]
10. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
11. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y; Cancelas JA
Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
[TBL] [Abstract][Full Text] [Related]
12. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
[TBL] [Abstract][Full Text] [Related]
13. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.
Ohnishi H; Kandabashi K; Maeda Y; Kawamura M; Watanabe T
Br J Haematol; 2006 Sep; 134(5):547-9. PubMed ID: 16856885
[No Abstract] [Full Text] [Related]
14. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
15. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
Gotlib J; Akin C
Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
[TBL] [Abstract][Full Text] [Related]
16. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
17. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.
Schmitt-Graeff AH; Erben P; Schwaab J; Vollmer-Kary B; Metzgeroth G; Sotlar K; Horny HP; Kreipe HH; Fisch P; Reiter A
Blood; 2014 Jan; 123(4):595-7. PubMed ID: 24458279
[No Abstract] [Full Text] [Related]
18. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
Helbig G; Kyrcz-Krzemien S
Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
[No Abstract] [Full Text] [Related]
19. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
Lierman E; Smits S; Cools J; Dewaele B; Debiec-Rychter M; Vandenberghe P
Leukemia; 2012 Jul; 26(7):1693-5. PubMed ID: 22301675
[No Abstract] [Full Text] [Related]
[Next] [New Search]
